Role of Litigation in Defining Drug Risks_JAMA / BMJ
Documents uncovered during the course of litigation shed light on real risks of drug-induced harm that would not otherwise be known.
Documents uncovered during the course of litigation shed light on real risks of drug-induced harm that would not otherwise be known.
The authors argue that recommendations for the expanded use of statins to stave off cardiovascular disease are NOT supported by the evidence.
The question is: will Eli Lilly succeed, once again, to divert public attention from the revelations contained in its internal documents about the company's illegal marketing practices and its failure to warn about lethal risks posed by its product?
NY Times reports: In March 2002, Lilly rejected plans to give psychiatrists guidance about how
to treat diabetes, "worrying that doing so would tarnish Zyprexa's reputation."
This is an addendum to yesterday's Infomail in which we disseminated disinformation issued by the U.S. Center for Disease Control (CDC). www.ahrp.org/cms/content/view/396/80
Federal Study Finds No Benefit of New Antipsychotic Drugs – WashPost/Wall StreetJ/NY Times Tue, 20 Sep 2005 The findings of a $44 million government sponsored study, CATIE, published in The New England Journal of Medicine, comparing an older generic antipsychotic to four new atypical antipsychotics, undercut the legitimacy of psychiatry’s…
Philadelphia Daily News Pharma Influence: Penn Psychiatrist Files Whistleblower Lawsuit – Investigtion Confirms Medicare Chief Lied to Congress Wed, 7 Jul 2004 “Drug companies not only write checks to hospitals, they write checks to politicians…They write checks to both sides of the aisle.” Two separate news reports provide a glimpse…
FDA to review “missing” drug company documents Fri, 31 Dec 2004 Related Link: Peter Breggin, MD RE: Eli Lilly’s Contentions that the BMJ Prozac Documents were Never Missing and Have No Significance In the final hours of 2004, an investigative reporter for the British Medical Journal obtained long “missing” Eli…
Infomail 2005 News Stories on Human Research Protection and Commentary by Vera Hassner Sharav Subscribe to the AHRP infomail list Dec 16: Drugs, Devices & Doctors – NYT Paul Krugman Dec 11: Scientific Fraud & Corruption on Both sides of Atlantic: Merck / Proctor & Gamble Dec 11: Gov Accountability…
Infomail 2005 News Stories on Human Research Protection and Commentary by Vera Hassner Sharav Subscribe to the AHRP infomail list Dec 16: Drugs, Devices & Doctors – NYT Paul Krugman Dec 11: Scientific Fraud & Corruption on Both sides of Atlantic: Merck / Proctor & Gamble Dec 11: Gov Accountability…
Failed Drug Treatments for Schizophrenia–Letters to the Editor – NYT Fri, 23 Sep 2005 Letters to the NY Times editor (below) demonstrate the combative reaction of stakeholders in the psychotropic drug industry to the evidence-based overthrow of psychiatry’s treatment recommendations. Psychiatrists who have financial contracts with psychotropic drug manfuacturers, have…
Statin-Cholesterol Guidelines–Industry influenced? Wed, 14 Jul 2004 Scientific journal editors are scrambling about how to react to bad publicity emanating from public disclosure that the scientific reports they have published are likely to be biased because the authors’ had financial ties to the companies whose drugs / devices they report…